Nventa Biopharmaceuticals Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 27

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

Nventa Biopharmaceuticals General Information

Description

Developer of therapeutics and drug delivery technologies. The company engages in the development of therapeutics for the treatment of viral infections and cancers, with a focus on diseases caused by the human papillomavirus.

Contact Information

Website
www.nventacorp.com
Formerly Known As
StressGen Biotechnologies
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 9381 Judicial Drive
  • Suite 180
  • San Diego, CA 92121
  • United States
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Acquirer
Akela Pharma
Corporate Office
  • 9381 Judicial Drive
  • Suite 180
  • San Diego, CA 92121
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nventa Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Nventa Biopharmaceuticals‘s full profile, request access.

Request a free trial

Nventa Biopharmaceuticals Patents

  • 68

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Nventa Biopharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2247308-A1 Adjuvant compositions comprising poly-ic and a cationic polymer Inactive 10-Jan-2008
US-20110038888-A1 Adjuvant compositions comprising poly-ic and a cationic polymer Inactive 10-Jan-2008
EP-2247308-A4 Adjuvant compositions comprising poly-ic and a cationic polymer Inactive 10-Jan-2008
US-20090041809-A1 Double-stranded locked nucleic acid compositions Inactive 07-Mar-2007
AU-2008222523-A1 Double-stranded locked nucleic acid compositions Inactive 07-Mar-2007 A61K39/39
To view Nventa Biopharmaceuticals’s complete patent history, request access »

Nventa Biopharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nventa Biopharmaceuticals FAQs

  • When was Nventa Biopharmaceuticals founded?

    Nventa Biopharmaceuticals was founded in 1990.

  • Where is Nventa Biopharmaceuticals headquartered?

    Nventa Biopharmaceuticals is headquartered in San Diego, CA.

  • What is the size of Nventa Biopharmaceuticals?

    Nventa Biopharmaceuticals has 27 total employees.

  • What industry is Nventa Biopharmaceuticals in?

    Nventa Biopharmaceuticals’s primary industry is Drug Delivery.

  • Is Nventa Biopharmaceuticals a private or public company?

    Nventa Biopharmaceuticals is a Private company.

  • What is the current valuation of Nventa Biopharmaceuticals?

    The current valuation of Nventa Biopharmaceuticals is .

  • What is Nventa Biopharmaceuticals’s current revenue?

    The current revenue for Nventa Biopharmaceuticals is .

  • How much funding has Nventa Biopharmaceuticals raised over time?

    Nventa Biopharmaceuticals has raised $278K.

  • When was Nventa Biopharmaceuticals acquired?

    Nventa Biopharmaceuticals was acquired on 22-May-2009.

  • Who acquired Nventa Biopharmaceuticals?

    Nventa Biopharmaceuticals was acquired by Akela Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »